CSL LIMITED's stock soared 5.02% during intraday trading on Friday, following positive regulatory news from the United Kingdom.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorisation for CSL's adjuvanted trivalent influenza vaccine, AUJEMFLU. The approval allows the vaccine to be marketed to protect adults aged 50 and over against flu, potentially opening a significant new market for the company's product portfolio.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.